| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22014 |
| Drug | Nirmatrelvir/Ritonavir |
| Brand | Paxlovid® |
| Indication | Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 08/03/2022 |
| Rapid review completed | 15/03/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Nirmatrelvir/Ritonavir (Paxlovid®) not be considered for reimbursement at the submitted price*. |
| Full pharmacoeconomic assessment commissioned by HSE | 05/05/2023 |
| Pre-submission consultation with Applicant | 08/09/2023 |
| Full submission received from Applicant | 01/02/2024 |
| Preliminary review sent to Applicant | 14/02/2024 |
| NCPE assessment re-commenced | 13/03/2024 |
| Factual accuracy sent to Applicant | 30/05/2024 |
| NCPE assessment re-commenced | 07/06/2024 |
| NCPE assessment completed | 20/06/2024 |
| NCPE assessment outcome | The NCPE recommends that Paxlovid be considered for reimbursement if cost-effectiveness can be improved* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. February 2025
